Esperion Pharmaceuticals and Corstasis Therapeutics, a privately-held biopharmaceutical company, have announced a definitive agreement under which Esperion will acquire Corstasis.

 

The deal brings Enbumyst (bumetanide nasal spray) into Esperion’s portfolio—the first and only FDA-approved nasal spray diuretic, cleared in September 2025 to treat edema in adults with congestive heart failure (CHF), liver disease, and kidney disease. 

 

Enbumyst provides a self-administered, outpatient therapy designed to bridge the gap between oral and IV diuretics. The transaction is expected to close in the second quarter of 2026.

 

“This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion’s momentum and advances our long-term Vision 2040. Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. 

 

"Enbumyst’s novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise,” said Sheldon Koenig, President and CEO of Esperion. 

 

“We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders – from patients and providers to employees and shareholders.”

 

“Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need. Today's acquisition validates our team's vision and approach,” said Ben Esque, CEO of Corstasis Therapeutics. “We are excited about the future of Enbumyst in Esperion’s hands and its ability to intervene in the patient setting to treat worsening heart failure at home.”

 

With an estimated 6.7 million Americans living with CHF, edema remains a major clinical challenge, particularly in severe cases. Enbumyst targets a large, growing population with unmet medical needs, offering Esperion a U.S. market opportunity exceeding $4 billion, with potential expansion into hepatic and renal indications including nephrotic syndrome.

 

The acquisition enhances Esperion’s commercial portfolio, strengthens long-term revenue potential, and aligns with Vision 2040, the company’s roadmap for delivering differentiated cardiovascular innovations.